Clinical Trial Search

Primary: Percentage of Participants Who Were Responders With Menstrual Blood Loss (MBL) Volume < 80 mL at Final Month and >= 50% Reduction in MBL Volume From Baseline to the…

Primary: Change in Therapeutic Window Size With Selected Contact at the Informity Programming Visit Compared to Baseline — 1.37; 1.80 milliampere (mA)

Primary: Number of Participants Who Received First Line Chemotherapy According to National Trial or Treatment Guideline — 27; 1 Participants

Primary: Receipt of the Annual Influenza Vaccine Among Index Patients. — 8804; 2795; 2163; 2123 Participants

Primary: Patient MARS Scores — 4.51; 4.26; 4.24 score on a scale

Primary: Change in Patient Activation at 6 Months — 4.3; 2.7 units on a scale — p=0.221

Primary: Percentage of Participants With Loss of Asthma Control — 40.5; 21.9; 27.0; 18.9 percentage of participants — p==0.0214

Primary: Number of Participants With Fiberoptic Use During Surgeries Requiring Lung Isolation — 42; 5 Participants — p=<0.0001

Primary: Number of Participants That Completely Switched From Combustible Cigarettes to Halo G6 E-Cigarettes — 8 Participants

Primary: 30 Second Chair Standing Test — 9.5 stands

Primary: Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and…

Primary: Baseline HIV DNA Reservoir: Total HIV DNA — 3.83; 3.67; 3.40 Log10 HIV DNA copies/10^6 CD4 T cells — p=0.048

Primary: Percentage of Participants Achieving Clinical Response on the Clinical Global Impression (CGI) Scale — 75.0; 75.0 percentage of participants

Primary: Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAE) — 0 Participants

Primary: Dry Eye Questionnaire 5 (DEQ-5) Score — 11.8; 11.8 score on a scale — p=0.02